Antag Therapeutics

AT-7687 is Antag’s GIPR antagonist – a peptide drug designed not just as a stand-alone product but also as a flexible therapeutic agent that can be used in combination with existing anti-obesity medications and emergent treatments of obesity.

GIP receptor (GIPR) antagonism represents a novel therapeutic approach that not only holds the potential to deliver significant weight loss but also improves long-term cardiometabolic outcomes in patients.

A first-in-human, single ascending dose (SAD)/multiple ascending dose (MAD) study of AT-7687 was successfully concluded in Q4 2025. AT-7687 is currently being evaluated in combination with semaglutide in a phase 2a study in patients with obesity and type 2 diabetes.

The Phase 2a study tests AT7687 as a combination treatment for people with obesity and type 2 diabetes, alongside semaglutide dose escalation.

Antag Therapeutics appointed Philip Just Larsen MD, PhD as Chief Executive Officer, highlighting his expertise in metabolic disease research and development.

Antag Therapeutics announced the election of Keith Leonard as Chairman of its Board of Directors, citing his 30 years of biopharmaceutical leadership.

Keith served as an officer in the U.S. Navy’s Civil Engineer Corps and earned degrees in business administration, mechanical engineering, history, and engineering from universities including the University of California, Los Angeles, and Berkeley.

Philip Just Larsen MD, PhD Chief Executive Officer

Antag Therapeutics is developing first-in-class GIPR antagonist therapies to address unmet medical needs in obesity treatment. We welcome inquiries from potential collaborators, investors, and scientific partners interested in our novel approach to metabolic disease.

Antag Therapeutics pioneers therapies for obesity, diabetes, and overweight, aiming for personalized, long-term health improvements without compromising tolerability.